Key Financial Data Terumo announced its financial results for the first quarter of fiscal year 2026. The company reported revenue of 831.5 billion yen and GAAP earnings per share of 74.25 yen. Previously disclosed results for the nine months ended December 31, 2025, showed that net profit attributable to parent company shareholders increased to 109.55 billion yen, up from 98.62 billion yen in the same period last year. Earnings per share were 74.25 yen, compared to 66.51 yen in the prior year. Operating profit rose to 144.87 billion yen, and revenue increased to 831.56 billion yen.
Drivers of Performance Growth The company's performance this quarter reached a record high, primarily driven by strong demand in the U.S. market, particularly in the Cardiovascular, and Blood and Cell Technologies business segments. Effective implementation of pricing strategies and global cost control measures led to profit growth outpacing revenue growth. Excluding foreign exchange effects, total revenue grew by 6%.
Performance of Three Major Business Segments The Cardiovascular business segment's revenue grew by 7% on a local currency basis, mainly driven by TIS and neurovascular businesses in the U.S. market, with the operating profit margin improving by 5 percentage points to 29%. The Blood and Cell Technologies segment achieved significant growth in plasma innovation, with increased demand in the cell and gene therapy field. The Medical Care Solutions business experienced a temporary revenue decline due to the divestiture of certain operations and supply issues.
Full-Year Guidance and Tariff Impact The company maintained its full-year performance guidance. The estimated full-year tariff impact is approximately 10 billion yen, primarily concentrated in the second half of the fiscal year. This figure is lower than the previous estimate of 17 billion yen, mainly due to adjustments in tariff rates for imports from Japan. The company plans to pass on the tariff impact through pricing measures.
Comments